PHARMACEUTICAL QUALITY MANAGEMENT SYSTEM: A REVIEW
Journal Title: International Journal of Drug Regulatory Affairs - Year 2014, Vol 2, Issue 3
Abstract
ICH is “International Conference on Harmonization” of technical requirements for registration of pharmaceuticals for human use. The goal of ICH is to discuss and establish common guidelines by bringing together three ICH regions i.e. USA, Japan and EU and to make information available on ICH, its activities and guidelines. The guidelines have become more relevant for Generic’s Drug Approval. Drug Development and manufactures are more and more global. Harmonization is considered more important than ever, as it facilitates work sharing, efficient use of resources and access to medicines. The objective of harmonization is meant for economical use of human, animal and other resources and the elimination of unnecessary delay in the global development and of availability of new medicines whilst maintaining safeguards on quality, safety and efficacy. The present discussion of the review is on ICH guidelines for quality control focussing mainly on Quality Risk Management (Q9). Quality control is a process that is used to ensure a certain level of quality in a product or service. It might include whatever action a business deems necessary to provide for the control and verification of certain characteristics of a product or service. Most often, it involves thoroughly examining and testing the quality of products or the results of services. The basic goal of this process is to ensure that the products or services that are provided meet specific requirements and characteristics, such as being dependable, satisfactory, safe and fiscally sound. Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the drug product across the product lifecycle. Two primary principles of quality risk management are: • The evaluation of the risk to quality should be based on scientific knowledge and Ultimately linked to the protection of the patient; and • The level of effort, formality, and documentation of the quality risk management process should be commensurate with the level of risk.
Authors and Affiliations
Sharma Shrey, Bodla R. B. , Shweta S, Pathak D. P.
Keywords
Related Articles
- EP ID EP349841
- DOI 10.22270/ijdra.v2i3.144
- Views 94
- Downloads 0
Regulatory aspects for Biologic Product licensing in Australia
The TG Act defines biological as product made, from or containing, human cells or human tissues, lives animal organs, cells or tissues, and that is used to treat or prevent disease or injury, Diagnose a condition of a pe...
MEDICINES HARMONIZATION IN WEST AFRICAN ECONOMIC AND MONETARY UNION (WAEMU) COUNTRIES
With the blessing of WHO, the different regions of West Africa engaged in Pharmaceutical regulation harmonization processes on the continent. Indeed, In west Africa, WAEMU actions on the matter ended in the production of...
IMPORTANCE OF DEFICIENCY RESPONSE IN PHARMACEUTICAL ENVIRONMENT FOR DRUG APPROVAL
This illustrates examples of series deficiencies, that’s how really company faces problem due to deficiency. It’s to convey the message if drug product manufacturer can visualize earlier all aspect of risks and manifest...
REGULATORY ENVIRONMENT FOR MEDICAL DEVICES IN NEW ZEALAND
Medical Devices are one of the most important health intervention tools available for the prevention, diagnosis and treatment of diseases and for patient rehabilitation. Although the Medical Devices market in the New Zea...
FORMULATION AND EVALUATION OF FAST DISINTEGRATING LOSARTAN POTASSIUM TABLETS BY FORMAL EXPERIMENTAL DESIGN
In the treatment of hypertension fast onset of action is the major concern. The problem of slow onset of action of drugs can be overcome by development of appropriate dosage forms. Fast disintegrating tablets in mouth ar...